Next week Antikor Biopharma will be in Barcelona for PEGS Europe with a fantastic program across all areas of protein-based therapies. Dr Deonarain will be chairing the first ADC session on Wednesday 6-November (Enhancing Payload Delivery and Improving Therapeutic Index) and then speaking in the afternoon on 'Next-Generation ADC Formats'. More amazing data on our innovative cMET FDC to be revealed. Looking forward to seeing some of you there. https://lnkd.in/ge4ZTX5 #PEGS #ADC #FDC #Oncology #Antikor
Antikor Biopharma Ltd
Biotechnology Research
Stevenage, England 1,575 followers
Innovating in and developing the next generation of smaller-format ADCs for cancer therapy and beyond
About us
Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.
- Website
-
http://www.antikor.co.uk
External link for Antikor Biopharma Ltd
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Stevenage, England
- Type
- Privately Held
- Founded
- 2014
- Specialties
- cancer, antibody, chemotherapy, chemistry, phage display, and antibody fragments
Locations
-
Primary
Get directions
Gunnels Wood Road
Stevenage, England SG12FX, GB
Employees at Antikor Biopharma Ltd
Updates
-
The preclinical data behind Antikor's innovative antibody Fragment Drug Conjugate (FDC) ANT-045 continues to impress with our latest gastric and pancreatic cancer PDX data. I'm looking forward to sharing this at the 36th EORTC-NCI-AACR molecular targets and cancer therapeutics symposium in Barcelona this week. We have a poster and Antikor was selected for a Spotlight presentation. https://lnkd.in/drZSZZrm #Antikor #FDC #ADC #Oncology #EORTC #AACR #NCI
36th EORTC-NCI-AACR Symposium
https://www.eortc.org
-
Antikor was one of the successful applicants to be awarded funding under the Innovate-UK Cancer Therapeutic Programme. This allows us to explore new avenues for our innovative antibody Fragment Drug Conjugate (FDC) technology. Hopefully we can add another product candidate to our pipeline ! #InnovateUK #CancerTherapeutics #Antikor #FDC #ADC https://lnkd.in/eg5RsCu8
£12 million funding awarded to advance innovative cancer projects
ukri.org
-
PEGS USA is the all-encompassing conference for antibody and protein technology with a fantastic oncology and ADC stream. Antikor will be presenting on Friday about our better penetrating FDC technology and latest data on our promising lead program ANT-045 for cMET expressing solid tumours. Maybe some hints about what's coming up for the future ! https://www.pegsummit.com #ADC #FDC #Antikor #PEGS
PEGS Boston Summit Protein & Antibody Engineering Summit | May 12-16, 2025 | Boston, MA
pegsummit.com